
Journal of the Formosan Medical Association, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Journal of the Formosan Medical Association, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Clinical and Molecular Hepatology, Год журнала: 2025, Номер 31(2), С. e208 - e209
Опубликована: Янв. 7, 2025
Язык: Английский
Процитировано
0The Kaohsiung Journal of Medical Sciences, Год журнала: 2025, Номер unknown
Опубликована: Янв. 19, 2025
Abstract An 8‐week regimen of glecaprevir/pibrentasvir is recommended for treatment‐naïve patients with chronic hepatitis C (CHC). In alignment the Taiwanese government's objective to eliminate by 2025, this study aimed provide real‐world evidence on use in kidney disease (CKD) using data from Taiwan Association Study Liver HCV Registry (TACR). CKD was defined an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 or higher proteinuria persisting over 3 months. Patients were categorized as having early (eGFR ≥45 ) pre‐end‐stage renal (pre‐ESRD) <45 ). Among 1072 who received at least one dose regimen, 1054 had available assessing sustained virologic response 12 weeks posttreatment (SVR12). The overall SVR12 99.6%, rates 99.7% pre‐ESRD and 99.6% patients. Subgroup analysis showed 100% efficacy genotype dyslipidemia, 99.5% diabetes, 99.4% cardiovascular disease, 96.9% a history cerebral vascular accident, 95.5% drug injection HIV co‐infection. Adverse events reported 16.8% patients, 0.8% experiencing serious events, only two cases treatment‐related. Renal function significantly improved, eGFR increasing 39.2 41.9 . Early rise 53.5 57.1, while improved 27.1 29.2 SVR12. concluded that highly effective, well‐tolerated, associated significant improvement CHC both pre‐ESRD.
Язык: Английский
Процитировано
0Journal of the Formosan Medical Association, Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0